Interaction Guide · Research summary

Can I take Matricaria Chamomilla with Clozapine?

Review Matricaria Chamomilla with Clozapine: timing and monitoring and possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

No clinical evidence establishes that clozapine changes the need for German chamomile or requires a particular dosing interval. Possible added sleepiness remains a theoretical concern for oral preparations.

What this answer covers

Matricaria chamomilla species-level entry; oral tea, flowering-top extracts and other preparations are not interchangeable. Roman chamomile is a different botanical.

Supplement or preparation
Matricaria chamomilla
Medication ingredient
clozapine

Which chamomile is covered

German chamomile may be called Matricaria chamomilla or Matricaria recutita. Roman chamomile is different. A study of a specific flowering-top extract cannot establish the same exposure or effects for tea, another extract or a skin product.

What the clinical study showed

A small trial gave 34 adults with primary insomnia standardized flowering-top extract or placebo for 28 days. Sleep outcomes and adverse events did not differ significantly. People with a history of psychotic disorder and those taking hypnotic medicines were excluded, so this was not a clozapine interaction study.

Why sleepiness is still considered

NCCIH describes the potential interaction with sedatives as theoretical. Clozapine itself can cause sleepiness and impaired coordination. Extra impairment is possible, but the study does not establish its frequency or severity for this combination. Lack of a demonstrated interaction does not prove safety.

No proven timing rule

No clinical evidence here establishes a need to add chamomile, change its amount or separate it from clozapine by a set number of hours. Review the exact oral product with the treating team before using it for sleep. Report troublesome new sleepiness or unsteadiness and avoid driving while impaired.

Evidence and practical considerations

Timing & monitoring

No evidence establishes a changed need, dose or timing with clozapine. Theoretical sedation concerns do not establish the current timing statement.

Exact scope
Matricaria chamomilla species-level entry; oral tea, flowering-top extracts and other preparations are not interchangeable. Roman chamomile is a different botanical. with Oral clozapine, RxNorm 2626 IN.
Medication form and route
oral clozapine; oral supplement

What remains uncertain

  • No quantified clozapine-specific interaction or validated spacing intervention.

Factors that may matter: Exact preparation; Other medicines and baseline clinical status.

Research conclusion: insufficient evidence · Evidence assessment: very low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: People prescribed clozapine.

Clozapine causes sedation and impaired performance, can contribute to falls, and carries dose-related seizure risk. CYP1A2, CYP3A4 and CYP2D6 participate in metabolism. Proposed therapeutic activity includes dopamine D2 and serotonin 5-HT2A receptor antagonism.

How this applies: Medication-specific safety context only; no direct botanical interaction or automatic dose change is established.

No named interaction with these counterparties or measured combined risk.

Source 2: original human clinical study

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: 34 adults with primary insomnia; lifetime psychotic disorder and current hypnotic medication excluded.

No significant primary sleep benefit or adverse-event difference; reported adverse events mild and transient.

How this applies: Interpret only within the stated preparation, population and endpoints.

No clozapine recipients; one preparation and small study cannot exclude rare interactions or represent every tea or extract.

Source 3: federal supplement safety guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: Users of the named supplement.

Identifies Matricaria recutita and Matricaria chamomilla as German chamomile names, distinguishes Roman chamomile, and describes sedative interactions as theoretical.

How this applies: Supplement-specific guidance interpreted alongside the clozapine label.

General guidance does not quantify a clozapine interaction or establish protective spacing.

Research assessment: · Open full citations ↗

Side effects & toxicity

Possible additional impairment warrants individual review because clozapine causes sedation and the supplement has sedative effects or a stated theoretical sedative-interaction concern; clinical magnitude is unmeasured.

Exact scope
Matricaria chamomilla species-level entry; oral tea, flowering-top extracts and other preparations are not interchangeable. Roman chamomile is a different botanical. with Oral clozapine, RxNorm 2626 IN.
Medication form and route
oral clozapine; oral supplement

What remains uncertain

  • No quantified clozapine-specific interaction or validated spacing intervention.

Factors that may matter: Exact preparation; Other medicines and baseline clinical status.

Research conclusion: supported with conditions · Evidence assessment: low

Read the supporting source summaries

Source 1: current product label

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: People prescribed clozapine.

Clozapine causes sedation and impaired performance, can contribute to falls, and carries dose-related seizure risk. CYP1A2, CYP3A4 and CYP2D6 participate in metabolism. Proposed therapeutic activity includes dopamine D2 and serotonin 5-HT2A receptor antagonism.

How this applies: Medication-specific safety context only; no direct botanical interaction or automatic dose change is established.

No named interaction with these counterparties or measured combined risk.

Source 2: original human clinical study

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: 34 adults with primary insomnia; lifetime psychotic disorder and current hypnotic medication excluded.

No significant primary sleep benefit or adverse-event difference; reported adverse events mild and transient.

How this applies: Interpret only within the stated preparation, population and endpoints.

No clozapine recipients; one preparation and small study cannot exclude rare interactions or represent every tea or extract.

Source 3: federal supplement safety guidance

nccih.nih.gov · Source check Sep 10, 2026

Population: Users of the named supplement.

Identifies Matricaria recutita and Matricaria chamomilla as German chamomile names, distinguishes Roman chamomile, and describes sedative interactions as theoretical.

How this applies: Supplement-specific guidance interpreted alongside the clozapine label.

General guidance does not quantify a clozapine interaction or establish protective spacing.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Prepared evidence-based article with explicit preparation and endpoint limits.
Research summary published

Article revision: 6f4af1f9e9429da6

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.